Antagonizing GIPR adds fire to the GLP-1R flame
Aaron Novikoff, Timo D. Müller
Abstract
Unimolecular co-agonists at the GLP-1/GIP receptors have recently achieved remarkable anti-obesogenic feats; yet, in a recent Phase 1 clinical trial, Véniant and colleagues report astounding body-weight loss, and an appreciable safety profile, in participants with obesity using the GLP-1R agonist/GIPR antagonist AMG 133.
Topics & Concepts
AgonistAntagonistReceptorEndocrinologyInternal medicineObesityWeight lossB2 receptorMedicinePharmacologyChemistryBradykininDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerPharmacology and Obesity Treatment